<DOC>
	<DOCNO>NCT00966329</DOCNO>
	<brief_summary>Patients HIV-1 infection HAART regimen include 2 NRTI/NtRTIs plus one following : 1 PI/ritonavir ATV/unboosted 1 NNRTI , randomize switch NNRTI/PI maraviroc ( 300 mg /12 h ) continue approach .</brief_summary>
	<brief_title>Switching Non-nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) Protease Inhibitor ( PI ) Maraviroc HIV Subjects</brief_title>
	<detailed_description>This 48 week randomize , prospective , control , open-label , proof-of-concept pilot clinical trial . Patients HIV-1 infection HAART regimen include 2 NRTI/NtRTIs plus one following : 1 PI/ritonavir ( lopinavir/ritonavir , atazanavir/ritonavir , fosamprenavir /ritonavir , tipranavir/ritonavir , darunavir/ritonavir ) ATV/unboosted ( regimen without tenofovir ) 1 NNRTI ( nevirapine efavirenz ) . Patients randomize switch NNRTI/PI maraviroc ( 300 mg /12 h ) continue approach . The primary endpoint would percentage patient maintain virological suppression week 48 .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Maraviroc</mesh_term>
	<mesh_term>Protease Inhibitors</mesh_term>
	<criteria>1 . HIV1 infect adult ( =/+18 year old ) . 2 . Patient diagnosis HIV infection , stable HAART include 2 NRTI/NtRTIs plus one following : 1 PI/ritonavir ATV/unboosted 1 NNRTI . 3 . Undetectable plasma HIV1 RNA ( VL &lt; 50 copies/mL ) HAART . 4 . Patient least one follow condition : Antiretroviralrelated gastrointestinal disturbance , Low patient 's satisfaction associate current regimen posology ( ritonavir use , ritonavir intoleranceâ€¦ ) , Any toxicity drug relate . 5 . Nadir CD4 cell count &gt; 350 cells/mm3 . 6 . Absence resistance mutation RT PR ( TrugeneTM ) 7 . Good treatment adherence . 8 . Voluntary write informed consent . 1 . Virologic failure previous antiretroviral regimen . 2 . Any antiretroviral resistance mutation previous resistance test . 3 . Dual/mixed X4 virus detect time point , include pretreatment ESTrofile test PBMC test do treatment switch . 4 . Acute infection uncontrolled chronic infection 2 month previous inclusion . 5 . Pregnancy fertile woman willing pregnant .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Switching</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Virological efficacy</keyword>
	<keyword>Lipid profile</keyword>
	<keyword>Tropism</keyword>
</DOC>